Oncogenes play a key role in the development of cancers. One of the most commonly mutated oncogenes in cancer is PI3Ka. It is found in approximately 13% of human cancers and 29% of breast cancer. There are three most common mutations of PI3Ka namely H1047R, E542K, and E545K. The approved PI3Ka inhibitors that are on the market are associated with significant on-target toxicities, including hyperglycemia, rash, fatigue, and diarrhea.
The company we are profiling today is OnKure Therapeutics Inc. (OKUR), which is developing a drug by the name OKI-219 that targets the PI3KaH1047R mutation.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com